Evidence map›Paper›PMID 36471329›Full record

ArticleJournal of biomedical science2022

Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer.

Che-Yuan Hu, Bing-Hua Su, Ya-Che Lee, Chung-Teng Wang, Mei-Lin Yang, Wan-Ting Shen, Jing-Ting Fu, Shih-Yao Chen, Wei-Yun Huang, Chien-Hui Ou and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of biomedical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Che-Yuan Hu *Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.ORCID http://orcid.org/0000-0001-5151-4552
Bing-Hua Su *School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Ya-Che LeeDepartment of Urology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.
Chung-Teng WangDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701401, Taiwan.
Mei-Lin YangDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701401, Taiwan.
Wan-Ting ShenDepartment of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701401, Taiwan.
Jing-Ting FuDepartment of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701401, Taiwan.
Shih-Yao ChenDepartment of Nursing, College of Nursing, Chung Hwa University of Medical Technology, Tainan, Taiwan.
Wei-Yun HuangDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701401, Taiwan.
Chien-Hui OuDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138, Sheng Li Road, Tainan, 704302, Taiwan.
Yuh-Shyan TsaiDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138, Sheng Li Road, Tainan, 704302, Taiwan.
Feng-Chih KuoDivision of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ai-Li ShiauDepartment of Microbiology and Immunology, College of Medicine, National Cheng Kung University, 1 University Road, Tainan, 701401, Taiwan. alshiau@mail.ncku.edu.tw.
Gia-Shing ShiehDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138, Sheng Li Road, Tainan, 704302, Taiwan. 00053@tnhosp.mohw.gov.tw.
Chao-Liang WuDitmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan. wumolbio@mail.ncku.edu.tw.ORCID http://orcid.org/0000-0001-7821-9406
Chia-Yi Christian Hospital · TWNational Cheng Kung University · TWNational Cheng Kung University Hospital · TWChung Hwa University of Medical Technology · TWMinistry of Health and Welfare · KRTaipei Medical University · TWTri-Service General Hospital · TW

Funding

Ditmanson Medical Foundation Chia-Yi Christian Hospital NCKUCYC-P-11101-2Ministry of Science and Technology, Taiwan 110-2314-B-006-024
6 · The paper itself

Abstract

backgroundCisplatin-based chemotherapy is the first line of treatment for bladder cancer. However, cisplatin induces muscle wasting associated with NF-κB and cancer cachexia. HOTAIR, an oncogenic long non-coding RNA (lncRNA), promotes cancer progression in different cancers. Crosstalk between HOTAIR and NF-κB is documented. Prothymosin α (ProT) plays important roles in cancer progression and inflammation. However, the potential link between HOTAIR, ProT, and cisplatin-induced cancer cachexia remains unexplored. Here, we investigated the contribution of HOTAIR in cisplatin-induced cancer cachexia and dissected the potential signaling cascade involving the epidermal growth factor receptor (EGFR), ProT, NF-κB, and HOTAIR. MATERIALS AND

methodsExpression of ProT and HOTAIR transcripts and their correlations in tumor tissues of bladder cancer patients and bladder cancer cell lines were determined by RT-qPCR. Next, levels of phospho-EGFR, EGFR, phospho-NF-κB, and NF-κB were examined by immunoblot analysis in human bladder cancer cells treated with cisplatin. Expression of HOTAIR in cisplatin-treated cells was also assessed by RT-qPCR. Pharmacological inhibitors and overexpression and knockdown approaches were exploited to decipher the signaling pathway. The murine C2C12 myoblasts were used as an in vitro muscle atrophy model. The syngeneic murine MBT-2 bladder tumor was used to investigate the role of mouse Hotair in cisplatin-induced cancer cachexia.

resultsExpression of ProT and HOTAIR was higher in bladder tumors than in normal adjacent tissues. There were positive correlations between ProT and HOTAIR expression in clinical bladder tumors and bladder cancer cell lines. Cisplatin treatment increased EGFR and NF-κB activation and upregulated ProT and HOTAIR expression in bladder cancer cells. ProT overexpression increased, whereas ProT knockdown decreased, HOTAIR expression. Notably, cisplatin-induced HOTAIR upregulation was abrogated by EGFR inhibitors or ProT knockdown. ProT-induced HOTAIR overexpression was diminished by NF-κB inhibitors. HOTAIR overexpression enhanced, whereas its knockdown reduced, cell proliferation, cachexia-associated pro-inflammatory cytokine expression, and muscle atrophy. Cachexia-associated symptoms were ameliorated in mice bearing Hotair-knockdown bladder tumors undergoing cisplatin treatment.

conclusionsWe demonstrate for the first time a critical role for HOTAIR and identify the involvement of the EGFR-ProT-NF-κB-HOTAIR signaling axis in cisplatin-induced cachexia in bladder cancer and likely other cancers. Our findings also provide therapeutic targets for this disease.

Indexed as

Antineoplastic AgentsCachexiaCisplatinRNA, Long NoncodingUrinary Bladder NeoplasmsAnimalsCell Line, TumorErbB ReceptorsHumansMiceMuscular AtrophyNF-kappa BSignal TransductionAntineoplastic AgentsCisplatinErbB ReceptorsHOTAIR long non-coding RNA, mouseHOTAIR long untranslated RNA, humanNF-kappa BRNA, Long NoncodingBladder cancerCachexiaChemotherapyCisplatinEGFRHOTAIRProthymosin α

Identifiers

PMID36471329
PMCPMC9724340
OpenAlexW4311284638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.